ENVB Stock Analysis: Buy, Sell, or Hold?
ENVB - Enveric Biosciences, Inc. Common Stock
$1.54
0.02 (1.66%)
â˛
5d:
-0.97%
30d:
+12.87%
90d:
-32.97%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ENVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ENVB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ENVB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ENVB is currently trading at $1.53, which is considered slightly high relative to its 30-day fair value range of $1.31 to $1.56.
Technical Outlook: Technically, ENVB is in a downtrend. Immediate support is located at $1.43, while resistance sits at $1.75.
Market Sentiment: ENVB scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+551.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENVB is in a downtrend. Immediate support is located at $1.43, while resistance sits at $1.75.
Market Sentiment: ENVB scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+551.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.31 -
$1.56
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 551.5% below Wall St target ($10.00)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.31 -
$1.56
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.43
Resistance Level
$1.75
Current Trend
Downtrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$10.00
(+551.5%)
Revenue Growth (YoY)
-7.3%
Share & Embed Analysis
Last updated: August 15, 2026 4:07 AM ET
Data refreshes hourly during market hours. Next update: 5:07 AM
Data refreshes hourly during market hours. Next update: 5:07 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 55 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 46 HOLD |
